In silico fusion of epsilon and alpha toxin genes of Clostridium perfringens type D and Clostridium septicum

Document Type : Full Research Paper

Authors

1 Faculty of science, Kharazmi University

2 Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization, (AREEO), Alborz, Karaj, Iran

Abstract

Recombinant DNA technology  is an in vitro molecular techniques to isolate and manipulate DNA fragments. Using this technique, construction chimeric molecules, called recombinant DNA molecules, then insert the recombinant molecules to living cells, replication and proliferation of the cells was possible. The fusion protein technology is the strategy to achieve rapid, cheap and efficient expression of proteins. Clostridium perfringens type D epsilon gene nucleotide sequence (etxD) and Clostridium septicum alpha gene (csa) were retrieved from GenBank. Then, to produce chimeric fusion protein, epsilon-alpha fusion gene was designed. Secondary and tertiary structures and characteristics of the fusion protein was determined by online software. The results showed that the designed fusion gene construction is suitable to expression of chimeric fusion protein.

Keywords

References

 Ballard J, Bryant A, Stevens D and Tweten RK (1992). Purification and characterization of the lethal toxin (alpha-toxin) of clostridium septicum. Infection and Immunity. 60(3): 784-790.

Ballard,J.,Crabtree,J.,Roe B.,A,Tweten.,1995,The primary structure of Clostridium septicum alpha- toxin exhibits similarity with that of Aeromonashydrophyla aerolysin,Infect Immun,63(1):340

      Ballard, J., Sokolov, Y., Yuan, W.L., Kagan, B.L., Tweten, R.K., 1993. Activation  and  mechanism  of  Clostridium  septicum  alpha  toxin.  Mol. Microbiol. 10, 627-634.

   Brown AS, Habeeb AFSA (1977). Structural studies on Epsilon toxin of Clostridium perfringens type D. Localisation of thesite of tryptic scission necessary for activation of epsilontoxin. Biochem Biophysl Res Commu. 73: 889-896.
    Dertzbaugh  MT  (1998).Genetically  engineered vaccines: an overview. Plasmid 39: 100-113.
    Garnier JF, Gibrat B, Robson GOR (1996). Secondary structure prediction method version IV, Methods in Enzymology, RF Doolittle Ed. 266: 540-553.

Gabay EL, Rolfe RD and Finegold SM (1981). Susceptibility of clostridium septicum to 23 antimicrobial agents. Antimicrobial Agents and Chemotherapy. 852-853.
   Gordon,  V.M.,  Nelson,  K.L.,  Buckley,  J.T.,  Stevens,  V.L.,  Tweten,  R.K., Elwood, P.C., Leppla, S.H., 1999. Clostridium septicum alpha-toxin uses glycosylphosphatidylinositol-anchored protein   receptors. J. Biol. Chem. 274, 27274-27280.

     Gordon,  V.M.,  Benz,  R.,  Fujii, K.,  Leppla,  S.H.,  Tweten,  R.K.,  1997.  Clostridium  septicum  alpha-toxin  is  proteolytically  activated  by  furin. Infect. Immun. 65, 4130-4134.
     Habeeb AFSA, Lee CL, Atassi MZ (1973). Conformational studies on  modified  proteins  and  peptides  VII  Conformation  ofepsilon prototoxin and epsilon toxin from Clostridium perfringens. Conformational changes associated with toxicity.Biochemica et Biophysica Acta. 322: 245-250.
     Hunter SEC, Clarck IN, Kelly DC, Titball RW (1992). Cloning and Nucleotide  Sequencing  of  the  Clostridium  perfringensEpsilon-Toxin Gene and Its Expression in Escherichia coli.Infect Immun. 60: 102-110.
 
     Hutchinson EG, Thornton JM (1996).”PROMOTIF- A program to identify structural motifs in proteins” Protein Sci. 5: 212-220.

 Hickey MJ, Kwan RYQ, Awad MM, Kennedy CL, Young LF, Hall P, Cordner LM, Lyras D, Emmins JJ and Rood JI (2008). Molecular and cellular basis of microvascular perfusion deficits induced by clostridium perfringens and clostridium septicum. PLoS Pathogens. 4(4): 1-9.

     Imagawa, T., Dohi, Y., Higashi, Y., 1994. Cloning, nucleotide sequence and expression  of  a hemolysin  gene  of  Clostridium  septicum.  FEMS Microbiol. Lett. 117, 287-292.

Liechti ME, Schob O, Kacl GM and Caduff B (2003). Clostridium septicum aortitis in a patient with colon carcinoma. Eur J Clin Microbiol Infect Dis. 22: 632-634.
 
 
     McClane BA (2001). Clostridium perfringens. Doyle MP, editor.Food microbiology: fundamentals and frontiers. Washington,DC: ASM Press. PP. 351-372.
      McDonel JL (1986). Toxins of Clostridium perfringens types A, B,C, D, and E, Dorner F, Drew H, editors. Pharmacology of bacterial toxins. Oxford: Pergamon Press. PP. 447-5
      Payne DW, Oysten P (1997). The Clostridium perfringens epsilon toxin. The Clostridia: Molecular biology and pathogenesis. Academic Press Limited: London. PP. 439-447.
     Pilehchian Langroudi R, Aghaei Pour K, Shamsara M, Jabbari AR, Habibi GR, Goudarzi H, Ghorashi SA  (2011). Fusion ofClostridium perfringens type D and B epsilon and beta toxin genes and it’s cloning in E. coli. Archives of Razi Institute. 66: 1-10.
 
     Rood JI, Cole ST (1991). Molecular genetics and pathogenesis of Clostridium perfringens. Microbio Rev. 55: 621-648.
 Smith-Slatas CL, Bourque M and Salazar JC (2006). Clostridiumsepticum infections in children: a case report and review of the literature. Pediatrics. 117(4): e796-e805.
     Zhang Y (2008). I-TASSER server for protein 3D structure prediction. BMC Bioinformatics. 9: 1-8.
     Zhang Y (2009). I-TASSER: Fully automated protein structure prediction in CASP8. Proteins S9: 100-113.
Veterinary Research & Biological Products
Volume 29, Issue 4
December 2016
Pages 128-135

Files

History

  • Receive Date: 27 September 2016
  • Accept Date: 27 September 2016

Share

How to cite

Statistics